Clinical testing of combinations of PD-1 pathway inhibitors with blockers of the vascular endothelial growth factor (VEGF) pathway, the CTLA-4 pathway, or TKIs have risen to prominence as therapies with the potential to generate radiologically measurable responses in over one-fourth of patients with advanced HCC.8 This evidence concerns the gene PDCD1 and hepatocellular carcinoma.